Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-01-10

Clinical Trial Update: Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Cavosonstat (N91115) in cystic fibrosis patients homozygous for the F508del-CFTR mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cavosonstat (Cavosonstat)

Snippet

Sponsor: Nivalis Therapeutics, Inc. | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED